AIDS疫苗研究进展  

Research progress of AIDS vaccine

作　　者：刘勇[1] 邵一鸣 

机构地区：[1]中国疾病预防控制中心性病艾滋病预防控制中心,北京100050

出　　处：《传染病信息》2009年第6期330-333,341,共5页Infectious Disease Information

基　　金：国家"十一五"科技重大专项(2008ZX1001-1010)

摘　　要：AIDS疫苗研究过程充满了坎坷和挫折。第一代基于gp120蛋白抗原的AIDS疫苗在欧美和泰国的Ⅲ期临床试验先后失败;代表第二代疫苗设计的Merck公司的腺病毒载体T细胞疫苗不但未提供保护性免疫,反而在特定人群中增加了感染几率。但科学家们仍不断推出新的疫苗设计思路,如免疫原筛选策略和基于结构生物学的免疫原设计策略等。当AIDS疫苗研究走完第25个年头的时候,在泰国开展的AIDSVAXB/E初始—ALVAC-HIV加强免疫的Ⅲ期临床试验中终于观察到了部分的保护效果,这一结果重新点燃了人们对AIDS疫苗研制成功的信心。AIDS vaccine research has encountered obstacles and setbacks. After the failure of first generation gpl20 based protein vaccine candidate AIDSVAX in the phaseⅢ clinical trials in Europe, America and Thailand, Merck＇s adenovirus vector-based second generation T cell vaccine did not provide protective immunity, but showed higher risk of HIV infection in particular subgroups of vaccinees. Despite all these defeats, scientists have been putting forward novel vaccine strategies such as immunogen screening and structure-based immunogen design. Subsequently after 25 years of research efforts, the AIDSVAX B/E prime-ALVAC-H1V boost regimen has shown partial protection in the phaseⅢ trials concluded in Thailand. The confidence for a successful AIDS vaccine has regained.

关 键 词：AIDS疫苗 临床试验 疫苗设计 

分 类 号：R512.91[医药卫生—内科学]